Structure Therapeutics
GPCR
26.68
-0.79
-2.88%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
26.68
-0.79
-2.88%
Live - 5344 symbols - heartbeat 400s ago
· 2026-10-08 06:41
Pre-market
26.46
-0.82%
After-hours
27.00
+1.20%
Overnight
26.78
+0.37%
- Market cap
- 1.90B
- P/E (TTM)i
- -8.81
- P/Bi
- 1.40
- EPSi
- -2.40
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on GPCR?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
105.83 +296.7%
Price target rangecurrent 26.68
Low70.00
Avg105.83
High145.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-09 | CCORF | -- | BUY | 111.00 |
| 2026-09-09 | H.C. Wainwright | -- | BUY | 70.00 |
| 2026-09-08 | LifeSci Capital | -- | BUY | 104.00 |
| 2026-09-08 | William Blair | -- | BUY | -- |
| 2026-09-08 | Jefferies | -- | BUY | 125.00 |
| 2026-09-08 | Clear Street | -- | BUY | 99.00 |
| 2026-08-17 | J.P. Morgan | -- | BUY | 100.00 |
| 2026-08-10 | Morgan Stanley | -- | BUY | 126.00 |
| 2026-08-10 | Citi | -- | BUY | 97.00 |
| 2026-08-07 | CCORF | -- | BUY | 111.00 |
| 2026-08-07 | William Blair | -- | BUY | -- |
| 2026-08-07 | Piper Sandler | -- | BUY | 93.00 |
| 2026-08-07 | Citizens JMP | -- | BUY | 110.00 |
| 2026-08-07 | Stifel | -- | BUY | 90.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 70.00 |
| 2026-08-06 | LifeSci Capital | -- | BUY | 104.00 |
| 2026-08-06 | BMO Capital | -- | BUY | 145.00 |
| 2026-08-06 | Citi | -- | BUY | 97.00 |
| 2026-06-11 | H.C. Wainwright | -- | BUY | 70.00 |
| 2026-06-09 | J.P. Morgan | -- | BUY | -- |
| 2026-06-08 | William Blair | -- | BUY | -- |
| 2026-06-07 | Cantor Fitzgerald | -- | BUY | 101.00 |
| 2026-06-05 | BMO Capital | -- | BUY | 145.00 |
| 2026-05-12 | H.C. Wainwright | -- | BUY | 100.00 |
| 2026-05-09 | LifeSci Capital | -- | BUY | 104.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 06:41:41 · For reference only, not investment advice and not tailored to your situation.